Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Treatment discontinuations due to adverse reactions occurred ... with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-founder, president and ...

Yancopoulos, Regeneron’s chief scientific officer ... to deliver the first FDA-approved recombinant monoclonal antibody treatment for any viral disease, and they picked one of the most ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...